Gregg Stone, Columbia University Medical Center, New York
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
A superiority for the anti-clotting drug bivalirudin for treating patients with acute coronary syndromes was detected when this was used as monotherapy, but not when this direct thrombin inhibitor was combined with glycoprotein IIb/IIIa inhibition. Thus found the ACUITY trial reported to the ACC’s Atlanta meeting by Gregg Stone of Columbia University. He told Audio Medica the bottom line finding from the study.
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
A superiority for the anti-clotting drug bivalirudin for treating patients with acute coronary syndromes was detected when this was used as monotherapy, but not when this direct thrombin inhibitor was combined with glycoprotein IIb/IIIa inhibition. Thus found the ACUITY trial reported to the ACC’s Atlanta meeting by Gregg Stone of Columbia University. He told Audio Medica the bottom line finding from the study.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.